Sales of biogenerics in US, Europe to soar-study
5th Sep 2005, 17:27 GMT
LONDON (Reuters) - Copycat versions of expensive biotech drugs could see $16.4 billion in sales in the United States and Europe by 2011 once regulatory curbs on so-called biogenerics use are gone, a study showed on Monday.
Latest news from Reuters: Health:
- Blow to chest can be fatal in child athletes: study
- Two Canada professors win right to toke up at work
- Diabetes drug may cut heart risks: study
- Most U.S. women in the dark about HPV: survey
- Red meat linked to some breast cancers: study
- Weight-loss surgery safety varies drastically: study
- Flu shot linked to tiny rise in risk for ailment
- Human natural painkiller beats morphine: research
- Radioactive iodine linked to thyroid disease
- Children showing hardening of arteries: study